Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 1interventionalRules rewrite

Phase 1: testing Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for Polycystic Ovary Syndrome (PCOS)

This trial will study the safety and how well it works of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.

Official registry: https://clinicaltrials.gov/study/NCT06143527 · The Foundation for Orthopaedics and Regenerative Medicine · enrollment listed as 20

What this phase means

Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells. The registry lists allocation as na. This trial will study the safety and how well it works of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.

They plan to enroll about 20 people at 2 sites. Taking part typically means an infusion or injection of a biologic plus check-ins.

Official title (unrewritten)

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for the Treatment of Polycystic Ovary Syndrome

Interventions: Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells

Primary outcome (registry wording): Safety: Adverse Events

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Women only
  • Ultrasound documented poly cystic ovary syndrome

Public study contact (from the registry)

Chadwick Prodromos, MD

847-699-6810

care@thepsci.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

2 listed

+ 1 sites outside the US on the same record

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseNew Haven, Connecticut
Not a traditional drug phase: testing Vitamin D 4000IU daily for Polycystic Ovarian Syndrome in Adolescent Females

This study is a double blind, dummy treatment (placebo) controlled, randomly assigned trial of study subjects with PCOS and low vitamin D to 2 groups- dummy treatment (placebo) and vitamin D replacement. Participants and investigators will be blinded to treatment modality until the end of the trial period

NCT04355572 · Official ClinicalTrials.gov record · Yale University

RecruitingPhase 3Aurora, Colorado
Phase 3: testing Semaglutide Injectable Product (Wegovy and/or Ozempic) for PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.

NCT05819853 · Official ClinicalTrials.gov record · University of Colorado, Denver

RecruitingNot a traditional drug phaseHouston, Texas
Determinants of Insulin Sensitivity by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis

The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race/ethnicity, body-mass index (BMI), and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditions.

NCT05950282 · Official ClinicalTrials.gov record · Ali Chappell

FAQ about this NCT record

Is NCT06143527 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06143527?

Phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06143527?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary